Poseida Therapeutics and Roche to focus on hematological malignancies

Poseida Therapeutics, Inc. entered into a broad strategic collaboration and license agreement with Roche focused on the development of allogeneic CAR-T therapy targeting hematological malignancies.

The global collaboration spans the research and development of several existing and new standard cell-based therapies for myeloma, B-cell lymphoma and other hematologic malignancies.

“We are very pleased to partner and collaborate with Roche, one of the world’s largest biotech companies with a successful track record in the discovery, development and commercialization of innovative medicines,” said Mark Gergen, CEO of Poseida.

“Roche is an ideal strategic partner for Poseida with its industry-leading oncology research and development capabilities, complementary technologies and expertise, and global regulatory and commercial capabilities. Working together, we look forward to advancing new allogeneic cell therapies based on Poseida’s technologies for patients fighting cancer.”

Details of the agreement

Under the agreement, Roche will receive from Poseida either exclusive rights or options to develop and commercialize allogeneic CAR-T programs in Poseida’s portfolio targeting hematologic malignancies. These include P-BCMA-ALLO1, an allogeneic CAR-T for the treatment of multiple myeloma, which is in a phase 1 study, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T for the treatment of B-cell malignancies with an IND expected in 2023.

The companies will also collaborate on a research program to create and develop next-generation features and enhancements for allogeneic CAR-T therapy, with which they will co-develop additional allogeneic CAR-T product candidates targeting existing and emerging hematologic targets.

For Poseida’s portfolio programs licensed or selected by Roche and the parties’ future collaborative programs, Poseida will conduct Phase 1 studies and produce clinical materials prior to transferring the programs to Roche for further development and commercialization. Roche will have full responsibility for late-stage clinical development and global commercialization of all products under the collaboration.

“We are excited to partner with Poseida to further explore the potential of allogeneic cell therapy to transform cancer care by developing off-the-shelf products that can address high unmet medical needs for a broad group of patients,” said James Sabri, Global Head of Pharmaceutical Partnerships at Roche.

“Posida’s differentiated platform technologies complement our ongoing internal efforts and partnerships to discover and develop cell therapies as the next generation of medicines for patients.”

Under the agreement, Poseida will receive $110 million upfront and may receive up to $110 million in the near term and other payments over the next several years. In addition, Poseida is eligible to receive research, development, launch and net sales and other payments, potentially up to $6 billion in aggregate value, as well as tiered royalties on net sales in the low double digits across various programs.

“We are delighted that Roche has taken the opportunity to partner with us and use Poseida’s unique allogeneic approach to develop CAR-T product candidates,” said Devon J. Shedlak, Chief Scientist of Poseida Cell Therapy.

“Using our proprietary technology and manufacturing process, including our booster molecule, we have the potential to develop and manufacture a product with high levels of stem cell memory T cells that correlate with potent antitumor efficacy in the clinic, at a scale that could potentially achieve more patients and ensure widespread commercial use.”

About Poseida Therapeutics

Poseida Therapeutics is a clinical-stage biopharmaceutical company using genetic engineering platform technologies to create next-generation cell and gene therapies.

The company has discovered and is developing a broad range of product candidates across multiple indications based on its core platforms, including the piggyBac non-viral DNA delivery system, the Cas-CLOVER site-directed gene editing system, and nanoparticle and AAV-based gene delivery technologies.

The technologies can be used – both individually and in combination – in many methods of cell and gene therapy. Poseida Therapeutics and Roche to focus on hematological malignancies

Back to top button